Pulmonary Hypertension Management Challenges in Pediatric ...
Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner...
Transcript of Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner...
![Page 1: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/1.jpg)
Pharmacotherapy of Pediatric Hypertension
FDA Corner
Mona Khurana, MD, Pediatric Team LeaderDivision of Pediatric and Maternal Health
Office of New DrugsCenter for Drug Evaluation and Research
Food and Drug Administration
![Page 2: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/2.jpg)
2
Outline• Landscape of Approved Drugs for Pediatric
Hypertension• Basis for Pediatric Approval• Challenges and Knowledge Gaps
![Page 3: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/3.jpg)
3
Disclosure Statement• I am employed by the US Food and Drug
Administration and I have no financial relationships to disclose relating to this presentation.
• The views expressed in this talk represent my opinions and do not necessarily represent the views of FDA.
![Page 4: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/4.jpg)
4
Currently Approved Pediatric Antihypertensive Drugs
![Page 5: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/5.jpg)
5
Currently Approved Pediatric Antihypertensive Drugs
![Page 6: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/6.jpg)
6
Initial Approach to Drug Approval• 2002 pediatric approval of enalapril > age 1 month*
– Extrapolation of adult efficacy – Multiple-dose (0.07-0.14 mg/kg/day) PK study in 40
hypertensive patients age 2 months to 16 years• Consistent PK profile across all ages studied
– Dose-ranging trial in 110 hypertensive patients age 6-16 years showed dose-dependent BP reduction
• < 50 kg: 0.625, 2.5, or 20 mg/day• > 50 kg: 1.25, 5, or 40 mg/day
• Subsequent data for other drugs showed no efficacy in pediatric age groups despite PK similarity to adults
*FDA Approved Vasotec Labeling (accessed from Drugs@FDA 2/9/20)
![Page 7: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/7.jpg)
7
Current Approach to Drug Approval • > 1 pediatric pharmacokinetic studies • Single controlled pediatric efficacy trial
– Double-blind, randomized dose-ranging trial + placebo – Randomized withdrawal trial
• Lead-in period of < 10 days• Initial randomization phase into > 2 active treatment arms (low,
medium, high dosage)• Second randomization to double-blind withdrawal to active
drug vs. placebo• Open-label safety phase• Change in systolic or diastolic blood pressure as primary
efficacy measure (validated surrogate endpoint)
![Page 8: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/8.jpg)
8
Basis for Pediatric Approval
![Page 9: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/9.jpg)
9
Other Approaches to Drug Approval• Reduce mean 10-year lag period between adult
and pediatric approval• Prevent off-label pediatric use post-approval in
adults• Leverage existing adult and pediatric (e.g. > age
6 years) clinical trial data from approved drugs to determine what additional data would be needed in target pediatric population (e.g. < age 6 years)
July 20, 2017 Addendum to ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population
![Page 10: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/10.jpg)
10
Extrapolation Approaches in Pediatric Programs
Increasing level of confidence in similarity of
disease/response
Increasing level of evidence
required from pediatric studies
~60% Pediatric Programsrequire at least 1 adequate, well-controlled efficacy trial (clinical or surrogate endpoint)
1 or more adequate-well controlled studies powered on a surrogate endpointDiabetes, anemia, idiopathic thrombocytopenia, treatment of venous thromboembolism, hypertension, hypercholesterolemia, asthma, etc.
1 or more adequate-well controlled studies powered on a clinically meaningful endpointBipolar disorder, systemic juvenile idiopathic arthritis, major depression, migraine, polyarticular JIA (pJIA), bronchopulmonary dysplasia, ADHD, nausea/vomiting, partial seizures (<4 y/o), respiratory syncytial virus, prophylaxis of venous thromboembolism, atopic dermatitis, etc.
Descriptive efficacy study without concurrent controlPlaque psoriasis, Neurogenic detrusor over-activity, pJIA (NSAIDs), etc.
Controlled study without formal statistical powerCommunity acquired pneumonia, nosocomial infections, skin and skin structure infections, etc.
PK/safety only (single dose level matching adult exposures)gastroesophageal reflux disease, bacterial sinusitis, herpes simplex, analgesics/anesthetics (well known MOAs; over 2 y/o), imaging products, melanoma (adolescents)
Small dose-ranging studies (randomization to multiple dose levels) Sedation, ulcerative colitis, Crohn’s, etc.
Small PK/PD studies (single dose level matching adult exposures)HIV, erosive esophagitis (infants), anesthetics, pulmonary arterial hypertension,
List partially adapted from Dunne et al. Pediatrics 2011
![Page 11: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/11.jpg)
11
Data Gaps• Only 2 drugs approved for oral use in patients
less than 6 years of age and none in neonates– Enalapril approved down to age 1 month – Candesartan approved down to age 1 year
• Need for more age-appropriate formulations with known bioavailability – Dosing flexibility– Dosing accuracy
![Page 12: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/12.jpg)
12
Failed Trials: Possible Contributing Factors
• Poor dose selection– Narrow dosage range studied– Exposure-response relationship presumed to be similar
between adults and pediatrics• Lack of age-appropriate formulation with
demonstrated bioequivalence to approved dosage form
• Choice of primary efficacy endpoint• Blood pressure measurement technique
![Page 13: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/13.jpg)
13
References• Momper JD, Mulugeta Y, Burckart GJ. Failed
Pediatric Drug Development Trials. Clinical Pharmacology & Therapeutics 98(3), 2015.
• Benjamin DK, Smith PB, Jadhav P, et al. Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range. Hypertension 51: 834-840, 2008.
![Page 14: Pharmacotherapy of Pediatric Hypertension...Pharmacotherapy of Pediatric Hypertension FDA Corner Mona Khurana, MD, Pediatric Team Leader Division of Pediatric and Maternal Health Office](https://reader033.fdocuments.net/reader033/viewer/2022050506/5f97ff295eba94580f0a4b89/html5/thumbnails/14.jpg)